Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as “Buy” by Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Thursday, Benzinga reports. They presently have a $115.00 price objective on the biotechnology company’s stock. Chardan Capital’s price objective would indicate a potential upside of 97.00% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. JPMorgan Chase & Co. upped their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Leerink Partners upped their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Finally, Citigroup started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They issued a “buy” rating and a $108.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $98.31.

Arrowhead Pharmaceuticals Trading Up 0.0%

ARWR stock traded up $0.01 during midday trading on Thursday, hitting $58.38. The company had a trading volume of 789,825 shares, compared to its average volume of 2,286,194. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 52 week low of $36.57 and a 52 week high of $95.49. The stock’s 50 day moving average price is $76.71 and its 200 day moving average price is $75.99. The stock has a market cap of $8.22 billion, a price-to-earnings ratio of -25.94 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. Arrowhead Pharmaceuticals’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.26) EPS. As a group, equities research analysts expect that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ARWR. Optiver Holding B.V. boosted its holdings in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Arrowhead Pharmaceuticals in the second quarter worth $39,000. Finally, First Horizon Corp boosted its holdings in Arrowhead Pharmaceuticals by 36.3% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 174 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.